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Clinical Reasoning:
Worsening neurologic symptoms in a
brain tumor patient
SECTION 1

A 65-year-old woman diagnosed with a right
parietal-occipital glioblastoma after presenting
with hemianopia was treated with 2 surgical resections including carmustine wafer placement, radiotherapy with concurrent chemotherapy with
temozolomide, and adjuvant chemotherapy with
temozolomide and bevacizumab, an anti-angiogenic
agent targeting vascular endothelial growth factor
(VEGF).

Seven months after the diagnosis, while receiving temozolomide and bevacizumab, the patient developed
headaches, subtle gait ataxia, memory difficulties, lethargy, and back pain, progressive over 3 weeks. She eventually developed a generalized tonic-clonic seizure and
was brought to an urgent care facility.
Questions for consideration:

1. What is the differential diagnosis?
2. Which examinations should be performed?
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SECTION 2

In a patient with glioblastoma presenting with worsening
neurologic symptoms, tumor progression with increased
tumor size and edema, eventually resulting in a seizure,
seems the most obvious diagnosis. However, the differential also includes other neurologic complications
(table), some of which are not necessarily indicative of
treatment failure, and that require specific management1:
•

Ischemic stroke can occur at increased incidence in patients with brain tumor as a result
of the cancer-related prothrombotic state, in
addition to radiotherapy-related vasculopathy in
arteries included within the radiation port, and
use of bevacizumab. As deep venous thrombosis
and pulmonary embolism are common in these
patients, paradoxical embolism may also occur.
• Intratumoral bleeding may occur spontaneously, especially in glioblastomas and oligodendrogliomas, and in the setting of bevacizumab,
anticoagulation, or thrombocytopenia.
• Seizures may develop even in stable tumors, and
can be difficult to recognize. This patient’s slow
deterioration could result from repeated nonconvulsive and subclinical seizures, which can mimic
slow progression of disease, only identifiable
through continuous EEG monitoring. Anticonvulsant intoxication is another possibility.
• Hydrocephalus may result from direct mechanical blockade of CSF flow (noncommunicating
hydrocephalus) or reduced CSF absorption due

Table

to radiotherapy or leptomeningeal spread (communicating hydrocephalus). Intracranial pressure is usually elevated, especially in patients
with rapidly progressive symptoms, but in
others normal-pressure hydrocephalus (NPH)
may develop slowly. Symptoms include progressive gait difficulties, psychomotor slowness,
and cognitive impairment; headaches, nausea,
and vomiting may be absent. Carefully monitoring ventricle size throughout the disease
course is important for the diagnosis.
• Leptomeningeal tumor spread or metastasis:
Tumor cells may gain access and thrive in the
subarachnoid space, causing progressive neurologic deterioration even when the original tumor
appears stable on the MRI. Symptoms may
include worsening headache, back pain, ataxia,
cognitive dysfunction, radiculopathy, cranial
nerve palsies, and hydrocephalus. The diagnosis
is confirmed by CSF cytology or typical MRI
findings, including enhancement in cranial
nerves, roots, and cerebellar folia, as well as cisterns and spinal cord nodules and deposits,
sometimes with a sugar coating appearance.
• Tumor pseudoprogression: Following radiotherapy, and usually within 2–3 months, some tumors
may display radiographic worsening resulting from
inflammation and necrosis in response to treatment, mimicking tumor progression. Recognizing
pseudoprogression is important because these

Potential causes of worsening of neurologic symptoms in patients with brain tumor

Differential diagnoses

Diagnostic tools

Key findings/pearls

Tumor progression

Neuroimaging (brain MRI with and without contrast; Increased size of enhancing and nonenhancing tumor; in patients on bevacizumab,
CT of head without contrast if emergency)
increase in nonenhancing tumor may be the only finding

Intratumoral bleeding

Neuroimaging

New T1 hypersignal lesions; may be difficult to differentiate from tumor calcifications
on the MRI and CT

Ischemic stroke

Neuroimaging

New fluid-attenuated inversion recovery or restricted diffusion lesions with a vascular
territory distribution; lesions may be difficult to differentiate from hypercellular or
hypoxic tumors, which may also display restricted diffusion

Seizures

EEG or video-EEG

May be subclinical, and a spot EEG may or may not show active seizures; continuous
EEG monitoring may be required

Hydrocephalus

Neuroimaging; lumbar puncture with opening
pressure

Reviewing older or pretreatment neuroimaging and comparing ventricles size over
longer periods of time may be needed; lumbar puncture can be performed if not
contraindicated by mass effect; intracranial pressure can be increased or normal

Leptomeningeal
dissemination

Brain and total spine MRI with and without
contrast; lumbar puncture with CSF cytology

CSF cytology has low sensitivity and repeat lumbar punctures may be needed; MRI may
be more sensitive, especially in the absence of bevacizumab treatment

Pseudoprogression

Neuroimaging

Usually develops 2–3 months following radiotherapy, although it can occur later in the
disease course; additional imaging techniques (magnetic resonance perfusion and
spectroscopy10) may be helpful

Corticosteroid
withdrawal

Neuroimaging

Diagnosis made by detailed review of corticosteroids use/doses (develops in the setting
of corticosteroids taper and rapidly improves with resumption of corticosteroids)

Herpetic
meningoencephalitis

Brain MRI; lumbar puncture with CSF HSV PCR

Typical signs of encephalitis on the MRI may be difficult to identify in the presence of
the tumor

Systemic infection/
metabolic disorders

Metabolic/infectious evaluation (CBC, electrolytes,
liver and renal function, urinalysis, chest X-ray,
thyroid function)

Absence of fever does not rule out infection; metabolic disorders resulting from
chemotherapy and tumor must be actively sought

Abbreviations: CBC 5 complete blood count; HSV 5 herpes simplex virus.
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Figure

MRI and autopsy findings

Brain MRI T1 postgadolinium images 7 months after the diagnosis show mild ventricular
dilation and hyperintense signal corresponding to residual tumor (A). In spite of progressive clinical worsening, subsequent scans done 11 (B) and 12 months (C) after diagnosis
show no significant progression of enhancing tumor. Corresponding fluid-attenuated
inversion recovery sequences at 7 months (D), 11 months (E), and 12 months (F) after
diagnosis confirm absence of progression of nonenhancing tumors, as occasionally seen
in patients on bevacizumab. This dissociation between neurologic deterioration and
absence of neurologic worsening poses a diagnostic dilemma. Autopsy shows extensive
leptomeningeal spread of the tumor, with hematoxylin & eosin low power (G) and high
power (H) demonstrating the coating of spinal cord and nerve roots by glioma (arrows).
(I) Tumor cells coating the cauda equina; glial fibrillary acid protein immunohistochemistry
further demonstrates the glial nature of the tumor, shown in brown (J). MRI of the spine
(not shown) had normal results, reflecting bevacizumab masking effects.

patients are not experiencing treatment failure and
a change in treatment is not indicated.
• Corticosteroid withdrawal: In some patients, it
is difficult to taper off corticosteroids, as worsening of brain edema may develop in the setting

of recent decreases in dose. Such patients
promptly improve with re-institution of corticosteroids, and benefit from a slower taper.
• Herpetic meningoencephalitis: Cranial radiotherapy and chemotherapy increase this infection risk. Signs of encephalitis may go
unrecognized in the MRI, confounded by the
presence of tumor-related abnormalities; the
diagnosis requires a high degree of suspicion.
• Metabolic causes such as systemic infection
(especially during chemotherapy), hyperglycemia (secondary to corticosteroids), liver failure
(chemotherapy-related hepatotoxicity or reactivation of viral hepatitis), and hypopituitarism
(from radiotherapy) may all cause neurologic
worsening in patients with a brain tumor.
Our patient’s MRI showed some ventricular dilation and faint contrast enhancement around the
right lateral ventricle occipital horn (figure, A and
D), without obvious tumor progression, bleeding,
or stroke. A total spine MRI with gadolinium, performed to investigate leptomeningeal disease, was
unremarkable. Platelets were normal and there was
no mass effect contraindicating a lumbar puncture
(LP), which was performed. CSF analysis showed
protein of 125 mg/dL, negative cytology and herpes
simplex PCR, and normal opening pressure. VideoEEG and routine urine and blood tests were unremarkable. The patient had been off corticosteroids
for several months.
Given the ventricular dilation, the patient received
a ventriculoperitoneal shunt in an attempt to treat
NPH, and was discharged. Questionable clinical
improvement was seen over the next few weeks.
In the following 6 months, while still on bevacizumab, the patient developed progressive confusion
and disorientation, worsening memory difficulties,
urinary incontinence, and more severe gait ataxia.
A repeat brain MRI showed no remarkable changes
in contrast enhancement (figure, B and C) or fluidattenuated inversion recovery (FLAIR) hyperintensities (figure, E and F). Her back pain worsened,
and symptoms of lumbosacral radiculopathy developed, but a repeat spine MRI was unremarkable.
CSF analysis showed protein 340 mg/dL, glucose
30 mg/dL, 2 leukocytes, and negative cytology.
EEG and blood and urine tests were again
noncontributory.
Questions for consideration:

1. What could be suspected despite normal CSF
cytology and stable imaging studies?
2. What could be done to improve symptoms?
GO TO SECTION 3
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SECTION 3

An intriguing finding in this patient is the lack of radiographic worsening despite marked clinical deterioration. In patients on bevacizumab, tumor progression
without increase in contrast enhancement is sometimes
observed, in a process of tumor cell cooption of existing
blood vessels that is independent of neoangiogenesis.2
In those patients, FLAIR hypersignal continues to
increase, but our patient showed only minimal FLAIR
changes, if any. Shunt malfunction could be a potential
explanation, and neurosurgical consultation was obtained. Neurotoxicity from radiotherapy could be considered, but there was no significant leukoencephalopathy,
and this type of complication typically occurs years later
in the disease course, in the rare patients who achieve
long-term survival.
Leptomeningeal spread remained the most likely
diagnosis, given the back pain, radiculopathy, and
increasing CSF protein, although cytology remained
negative. A careful look at the brain MRI (figure, C)
discloses some enhancement lining the ventricles, providing a diagnostic clue, but that finding is nonspecific
and the spine MRI results were normal. Radiotherapy
to the lumbosacral spine was considered for symptom
relief, but not pursued given the absence of radiographic abnormalities or diagnostic confirmation.
The patient resumed bevacizumab and temozolomide but continued to decline. Several shunt revisions
were performed with no improvement. Her neurologic
symptoms rapidly deteriorated and she died a few weeks
later.
On autopsy, macroscopic examination of the brain
revealed infiltration of the septum pellucidum by a
mucoid tumor tissue, with intraventricular and periventricular dissemination. Macroscopic examination
of the spinal cord showed disseminated tumor coating
of the leptomeninges and subarachnoid spaces, with
nodularity and thickening of spinal roots and cauda
equina. Microscopic findings are shown in the figure,
G–J. The diagnosis of widespread leptomeningeal
tumor was confirmed.
DISCUSSION Our patient presented with symptoms
suggestive of leptomeningeal metastasis (LM) during
treatment with bevacizumab. Repeated CSF cytology
and MRI failed to confirm LM, and there was a
marked dissociation between symptoms and radiographic findings; the diagnosis could only be confirmed by autopsy.
LM is an increasingly frequent complication of
cancer, and while therapeutic options are limited,
establishing this diagnosis is important for prognosis and institution of palliative treatments such as
focal radiotherapy.
Confirming the diagnosis of LM can be challenging. CSF cytology sensitivity is approximately only
e60
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50% at the first LP, increasing to up to 90% with
3 repeat LPs3,4; analysis of large volumes of CSF
may also improve sensitivity. Cytology sensitivity is
particularly lower in solid tumors, especially in glioblastoma.5 The identification of CSF circulating
tumor cells through rare cell capture technology
may facilitate the diagnosis,4 but this methodology
is limited to epithelial tumors, and not helpful in
gliomas. In solid tumors, the diagnosis of LM remains
heavily dependent on the MRI, a more sensitive technique than cytology.6,7
This patient was receiving the VEGF inhibitor
bevacizumab, known to confound interpretation of
MRI contrast enhancement. Proangiogenic factors
secreted by tumors lead to the formation of new capillaries, and these neovessels are fenestrated and lack
blood–brain barrier (BBB) properties. This disrupted
BBB provides the basis for imaging tumors on
contrast-enhanced MRI. VEGF promotes vascular
permeability in these vessels, and anti-VEGF therapies may thus decrease contrast enhancement, preventing accurate tumor visualization. This could
explain why the exuberant leptomeningeal disease
seen in the autopsy, with widespread coating of spinal
cord and nerve roots, was not apparent on the patient’s MRI despite obvious symptoms. This clinical
and radiologic dissociation has also been reported in 2
patients receiving bevacizumab for lung cancer brain
metastases, both presenting with LM and normal
MRIs.8 In a retrospective study of bevacizumab to
treat gliomas with LM, it was noted that in spite of
radiographic improvements, some patients experienced worsening of symptoms, once again suggesting
masking effects of this agent.9
It is important to fully evaluate patients with primary
or metastatic brain tumors presenting with neurologic
deterioration in order to recognize causes that require
specific neurologic management. Leptomeningeal spread
is a potential cause of unexplained neurologic deterioration in glioma patients treated with anti-angiogenic
agents, and interpreting contrast-enhanced MRI in this
setting can be challenging.
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